Your browser doesn't support javascript.
loading
Immediate Breast Reconstruction Does Not Have a Clinically Significant Impact on Adjuvant Treatment Delay and Subsequent Survival Outcomes / 한국유방암학회지
Journal of Breast Cancer ; : 109-119, 2019.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-738411
Biblioteca responsável: WPRO
ABSTRACT

PURPOSE:

The use of immediate breast reconstruction (IBR) has been debated because it may be a causative factor in adjuvant treatment delay and may subsequently increase the probability of recurrence. We investigated whether IBR was related to adjuvant treatment delay and survival outcomes.

METHODS:

We retrospectively analyzed the duration from operation to adjuvant treatment administration and survival outcomes according to IBR status among patients with breast cancer who underwent mastectomy followed by adjuvant chemotherapy from January 2005 to December 2014. Propensity score matching was performed to balance the clinicopathologic baseline characteristics between patients who did and did not undergo IBR.

RESULTS:

Of 646 patients, 107 (16.6%) underwent IBR, and the median follow-up was 72 months. The median duration from surgery to adjuvant chemotherapy was significantly longer in patients who underwent IBR than in those who did not (14 vs. 12 days, respectively, p = 0.008). Based on propensity score matching, patients who underwent IBR received adjuvant therapy 3 days later than those who did not (14 vs. 11 days, respectively, p = 0.044). The duration from surgery to post-mastectomy radiation therapy (PMRT) did not significantly differ between the 2 groups. Local recurrence-free survival, regional recurrence-free survival, systemic recurrence-free survival, and overall survival were also not significantly different between the 2 groups (p = 0.427, p = 0.445, p = 0.269, and p = 0.250, respectively). In the case-matched cohort, survival outcomes did not change.

CONCLUSION:

IBR was associated with a modest increase in the duration from surgery to chemotherapy that was statistically but not clinically significant. Moreover, IBR had no influence on PMRT delay or survival outcomes, suggesting that it is an acceptable option for patients with non-metastatic breast cancer undergoing mastectomy.
Assuntos

Texto completo: Disponível Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Recidiva / Mama / Neoplasias da Mama / Estudos Retrospectivos / Estudos de Coortes / Seguimentos / Mamoplastia / Quimioterapia Adjuvante / Radioterapia Adjuvante / Implantes de Mama Tipo de estudo: Estudo de etiologia / Estudo de incidência / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos Idioma: Inglês Revista: Journal of Breast Cancer Ano de publicação: 2019 Tipo de documento: Artigo
Texto completo: Disponível Base de dados: WPRIM (Pacífico Ocidental) Assunto principal: Recidiva / Mama / Neoplasias da Mama / Estudos Retrospectivos / Estudos de Coortes / Seguimentos / Mamoplastia / Quimioterapia Adjuvante / Radioterapia Adjuvante / Implantes de Mama Tipo de estudo: Estudo de etiologia / Estudo de incidência / Estudo observacional / Estudo prognóstico / Fatores de risco Limite: Feminino / Humanos Idioma: Inglês Revista: Journal of Breast Cancer Ano de publicação: 2019 Tipo de documento: Artigo
...